Suppressed Science and Corrupted Research

Now

The petroleum industry's own research confirmed the danger of fossil fuels decades before it became public knowledge. Research funded by the American Petroleum Institute in 1954 found that fossil fuel combustion had already raised atmospheric CO₂ by about 5%. In 1968, a report the API commissioned from the Stanford Research Institute predicted year-2000 CO₂ levels almost exactly, warning of "significant" temperature increases and "severe" environmental damage. In 1977, Exxon senior scientist James Black presented to the company's management committee a detailed analysis confirming that burning fossil fuels would cause significant global warming. Over the following decade, Exxon built one of the most sophisticated climate research programs in existence — installing CO₂ sensors on its supertanker, developing climate models, and publishing peer-reviewed research confirming the link. A 2023 study in Science by Supran, Rahmstorf, and Oreskes showed that Exxon's internal projections from the 1970s and 1980s were remarkably accurate — most of them forecast the warming that subsequently occurred, and were at least as skillful as independent academic and government models. The industry then pivoted from conducting climate science to funding its denial. The Global Climate Coalition — whose members included Exxon, Shell, BP, and the API — buried a 1995 internal report by its own scientific advisors confirming that the greenhouse effect "is well established and cannot be denied," and spent $13 million on advertising against the Kyoto Protocol alone. ExxonMobil spent more than $30 million on think tanks promoting climate doubt. Between 2003 and 2010, conservative foundations — Koch-affiliated foundations prominent among them, and increasingly untraceable conduits such as Donors Trust — channeled more than $550 million to 91 organizations of the climate counter-movement. The result was four decades of policy paralysis on a crisis the industry's own scientists had accurately predicted — during which global CO₂ emissions nearly doubled.

The template for this approach was established decades earlier with leaded gasoline. In 1921, General Motors researcher Thomas Midgley Jr. discovered that tetraethyl lead eliminated engine knock — despite having filed a patent for an alcohol-based antiknock blend the previous year. Ethanol worked but could not be monopolized; lead could. GM and Standard Oil formed the Ethyl Corporation to market it. Within three years, at least 15 workers at manufacturing plants had died violently insane — hallucinating, seizing, requiring straitjackets — while hundreds more were poisoned. Robert Kehoe, simultaneously a University of Cincinnati professor and the Ethyl Corporation's chief medical consultant for 33 years, then controlled both the research and its interpretation: his Kettering Laboratory, funded by GM, DuPont, and Ethyl, held a near-monopoly on lead health data for half a century, while his "show me the data" doctrine demanded proof of harm that only his industry-funded lab could produce. When Caltech geochemist Clair Patterson demonstrated in 1965 that lead burdens in industrial societies were roughly 100 times pre-industrial baselines, the industry mounted a campaign to discredit him. After leaded gasoline was finally phased out, Americans' average blood lead levels fell by more than 75%. The same constellation of companies — GM, Standard Oil of California, Firestone, and Phillips Petroleum — were convicted in a 1949 federal antitrust case of conspiring to monopolize the sale of buses and supplies to National City Lines — the holding company they financed, which bought up transit systems in dozens of American cities and replaced electric streetcars with GM buses running on their fuel and tires; GM was fined $5,000 and its convicted executive $1. The Kehoe paradigm — assume a product is safe until harm is proven, while controlling the means of proving it — became what epidemiologist David Michaels identifies as the template adopted by the tobacco, asbestos, chemical, and fossil fuel industries for evading evidence that their products caused harm.

The tobacco industry stated the strategy explicitly. A 1969 Brown & Williamson internal memo read: "Doubt is our product." The industry's own research had confirmed the cancer link decades earlier — scientists were fired and silenced, documents were destroyed, and in 2006 a federal judge issued a more than 1,600-page RICO verdict finding a decades-long conspiracy to deceive the public. The sugar industry deployed the same approach: the Sugar Research Foundation paid Harvard scientists $6,500 to write a two-part review, published in the New England Journal of Medicine in 1967, systematically blaming dietary fat — not sugar — for heart disease. The funding was never disclosed. When a separate industry-funded study found evidence linking sucrose to both elevated triglycerides and cancer, the foundation terminated funding and the results were never published. The same Harvard researcher who accepted the payment, D. Mark Hegsted, went on to head nutrition at the USDA and help draft the 1977 forerunner of the federal dietary guidelines — shaping guidance that made fat the primary villain while U.S. adult obesity rose from 13% in the early 1960s to over 40%.

The pattern extends across industries and decades. 3M's own studies showed by 1978 that PFOS was "more toxic than anticipated" — a monkey study had to be stopped after all the animals died within days — while DuPont documented PFOA's toxic effects on workers' children as early as 1981 and concealed its findings from the EPA for 20 years; today, nearly all Americans have PFAS in their blood. In the 1920s, the U.S. Radium Corporation knew that radium was killing the young women who painted luminous watch dials in its factories — their jaws were disintegrating from radiation exposure — but the company altered the findings of the Harvard scientists it had commissioned and pressed doctors to attribute the deaths to other causes, and fought the workers' lawsuits for years. In the late 1950s, the German pharmaceutical company Chemie Grünenthal marketed thalidomide as a sedative safe for pregnant women despite inadequate testing; thousands of children were born with severe limb malformations before it was withdrawn — a disaster averted in the United States largely because FDA reviewer Frances Kelsey refused to approve it without adequate safety data. In each of these cases, the science was known or knowable. In each case, it was suppressed, corrupted, or ignored because acting on it would have reduced revenue. The pattern is structural: when an institution's survival depends on the continued sale of a product, evidence that the product causes harm becomes a threat to be managed — not a finding to be acted on.